Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (159) Apply Press releases filter
- Basic page (28) Apply Basic page filter
- Pipeline (19) Apply Pipeline filter
- Corporate presentations (16) Apply Corporate presentations filter
- Shareholder meeting (16) Apply Shareholder meeting filter
- Team member (15) Apply Team member filter
- Videos (14) Apply Videos filter
- Financial reports (9) Apply Financial reports filter
- Analyst (6) Apply Analyst filter
- Webcasts and audio (5) Apply Webcasts and audio filter
- Event (3) Apply Event filter
- Investor contact (3) Apply Investor contact filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
CTL019 receives FDA approval for paediatric, young adult r/r B-cell ALL
London, UK – 30 August 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy g
Oxford BioMedica to Present at Rodman & Renshaw Annual Global Investment Conference, New York
Oxford, UK – 5 September 2017: Oxford BioMedica plc (“Oxfo
Oxford BioMedica notes the sBLA submission to FDA for Kymriah™ in adult patients with r/r DLBCL
Oxford, UK – 31 October 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy
Oxford BioMedica notes the sBLA submission to FDA for Kymriah™ in adult patients with r/r DLBCL
Oxford, UK – 31 October 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy
Oxford BioMedica notes the sBLA submission to FDA for Kymriah™ in adult patients with r/r DLBCL
Oxford, UK – 31 October 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy
Oxford BioMedica notes the CTL019 MAA submission to the EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK – 06 November 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today not
Oxford BioMedica notes the CTL019 MAA submission to the EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK – 06 November 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today not
Oxford BioMedica notes the primary analysis results from the pivotal JULIET trial demonstrating that Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Oxford, UK – 11 December 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene
Oxford BioMedica notes the US FDA Priority Review for Kymriah™ for adults with r/r DLBCL and EMA accelerated assessment for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK – 17 January 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy